Pfizer gets a small revenue boost from making drugs for Zoetis; FDA fires off its first warning letter since passage of the DQSA;

> It may have been a tough year for Pfizer ($PFE), but it says it picked up $132 million from the transitional manufacturing and supply agreements with Zoetis ($ZTS), the animal health operation it spun off. Release

> The FDA has sent a warning letter to Avella of Deer Valley, a Phoenix, AZ, compounding pharmacy that it says is not meeting the standards defined under the recently passed Drug Quality and Security Act, requiring prescriptions for any compounded products. Letter

> CordenPharma Colorado (CPC) says its API manufacturing facility in Boulder has received the Potent Compound Safety Certification by SafeBridge Consultants for its ability to safely handle potent APIs and compounds of unknown toxicity and potency. Release

> Northwest Biotherapeutics has a new agreement with contract manufacturer Cognate Bioservices to scale up production of its DCVax-L and DCVax-Direct products. Report

> The National University of Ireland at Galway (NUI Galway), the first facility in Ireland capable of manufacturing stem cells, has been licensed by regulators there to make stem cells for clinical trials. Story

And Finally... The All India Organization of Chemists & Druggists (AIOCD) has contracted out the manufacture of some over-the-counter medicines to help it better compete with foreign retailers entering Indian markets. Story